https://icosagen.eeKoduleht - IcosagenMuudame ideed reaalsuseks Icosagen on pühendunud Eesti biotehnoloogiaettevõte, mis tegeleb terapeutiliste antikehade arendamise ja diagnostiliste rekombinantsete valkude tootmisega imetajate rakkudes nii teadusuuringute kui ka in vitro diagnostika tarbeks. Loe lisaks Meist Teenused Klientide tagasiside “Fast responses, great flexibility, transparency, collaborative spirit, high quality” Ridgeline Kliki siia”Fast reply, quality of reports, good product profile” Pharis Biofarmaceuticals […]
Name
ICO Park OÜ
Registry code
12401945
VAT number
EE101603034
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
08.01.2013 (12)
Financial year
01.01-31.12
Capital
2 502.00 €
Activity
68201 - Rental and operating of own or leased real estate
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Icosagen AS 10565884 | 100% - 2 502.00 EUR | - | - | Founder |
| Mart Ustav
| - | Board member | - |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | 282 969.33 € | 36 939.83 € | 9 696.25 € | 3 |
| 2024 Q3 | 295 318.66 € | 31 687.74 € | 10 393.17 € | 3 |
| 2024 Q2 | 296 067.01 € | 43 945.27 € | 9 312.81 € | 3 |
| 2024 Q1 | 389 236.45 € | 64 078.31 € | 13 579.91 € | 3 |
| 2023 Q4 | 267 079.33 € | 24 149.03 € | 8 793.68 € | 3 |
| 2023 Q3 | 255 116.63 € | - | 8 868.2 € | 3 |
| 2023 Q2 | 181 720.22 € | - | 8 711.69 € | 3 |
| 2023 Q1 | 204 094.29 € | - | 10 870.8 € | 3 |
| 2022 Q4 | 236 005.27 € | 8 553.31 € | 8 055.31 € | 3 |
| 2022 Q3 | 151 401.12 € | 8 479.91 € | 8 599.24 € | 3 |
| 2022 Q2 | 168 511.52 € | 9 970.74 € | 8 590.81 € | 3 |
| 2022 Q1 | 160 018.5 € | 15 590.72 € | 7 774.66 € | 3 |
| 2021 Q4 | 146 681.13 € | 22 947.63 € | 6 914.65 € | 3 |
| 2021 Q3 | 105 870.3 € | 17 166.14 € | 6 313.93 € | 3 |
| 2021 Q2 | 125 191.76 € | 20 963.99 € | 6 021.36 € | 3 |
| 2021 Q1 | 118 510.44 € | 23 445.66 € | 7 616.75 € | 3 |
| 2020 Q4 | 101 005.93 € | 10 486.38 € | 6 031.65 € | 3 |
| 2020 Q3 | 80 040.41 € | 5 819.43 € | 6 040.77 € | 3 |
| 2020 Q2 | 102 922.22 € | 16 903.7 € | 5 958.82 € | 3 |
| 2020 Q1 | 128 861.1 € | 22 847.13 € | 7 027.01 € | 3 |
